Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      

This page is updated frequently with new Mammal-related patent applications.




Date/App# patent app List of recent Mammal-related patents
05/19/16
20160139153 
 Biomarkers for seizures patent thumbnailnew patent Biomarkers for seizures
The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject.
The Trustees Of The University Of Pennsylvania


05/19/16
20160138046 
 Compositions and methods directed to crispr/cas genomic engineering systems patent thumbnailnew patent Compositions and methods directed to crispr/cas genomic engineering systems
The invention relates to engineered crispr/cas9 systems for genomic modification in mammalian cells. The present specification describes the design and testing of a polynucleotide encoding the streptococcus pyogenes (s.
System Biosciences, Llc


05/19/16
20160138027 
 Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) patent thumbnailnew patent Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
Compositions and methods for treating diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) are disclosed. The invention is based in part on the discovery that protein mediator of amino acid signaling to mtor (mortor) is involved in amino acid-induced translocation of mtorc1 to lysosomes where mortor forms a signaling complex with mtorc1, ragulator, and rag gtpases, which controls protein synthesis.
The Board Of Trustees Of The Leland Stanford Junior University


05/19/16
20160137629 
 Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi patent thumbnailnew patent Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (pet) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body.
Piramal Imaging Sa


05/19/16
20160136347 
 Ambulatory lung assist device with implanted blood pump and oxygenator patent thumbnailnew patent Ambulatory lung assist device with implanted blood pump and oxygenator
The present disclosure provides a system for oxygenating blood. The system may include an implantable blood pump that may draw a supply of blood from the circulatory system of a mammalian subject, such as a human being.
Heartware, Inc.


05/19/16
20160136268 
 Mammalian milk osteopontin for enhancing immune responsiveness patent thumbnailnew patent Mammalian milk osteopontin for enhancing immune responsiveness
The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof..
Arla Foods Amba


05/19/16
20160136245 
 Methods of treating pain using protein solutions patent thumbnailnew patent Methods of treating pain using protein solutions
Methods and compositions for treating pain in mammalian subjects are provided. The methods include obtaining blood or a fraction of blood from the subject, measuring a therapeutic indicator in the blood or in the fraction blood, and administering an anti-inflammatory composition to the subject if the therapeutic indicator is equal to or above a threshold level.

05/19/16
20160136198 
 Use of immobilization particles for removal of microorganisms and/or chemicals patent thumbnailnew patent Use of immobilization particles for removal of microorganisms and/or chemicals
Method for immobilizing a target microorganism or target chemical found in a mammal includes introducing into a gastrointestinal tract of the mammal immobilization particles including immobilization molecules capable of attaching to the target microorganism or the target chemical, which immobilization molecules are attached to one or more portions of a structure that is capable of inhibiting contact between tissues of the gastrointestinal tract and the target microorganisms or target chemicals attached to the immobilization molecules.. .
Nubiome, Inc.


05/19/16
20160136197 
 Pharmaceutical compositions comprising a gpg oligodeoxynucleotide and cyclic di-gmp patent thumbnailnew patent Pharmaceutical compositions comprising a gpg oligodeoxynucleotide and cyclic di-gmp
The present invention relates to pharmaceutical compositions comprising an immunostimulatory amount of at least two immunopotentiators, wherein a first immunopotentiator is a non-methylated cytidyl guanosyl oligodeoxynucleotide (cpg odn) and a second immunopotentiator is 3′,5′-cyclic diguanylic acid (c-di-gmp), and a pharmaceutically acceptable carrier. The invention also relates to the use of such pharmaceutical compositions for the induction of an immune response against tumor-specific antigens.
Intervet Inc.


05/19/16
20160136149 
 Heteroaryl linked quinolinyl modulators of roryt patent thumbnailnew patent Heteroaryl linked quinolinyl modulators of roryt
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

05/19/16
20160136126 
new patent

Pharmaceutical compositions of anisomelic acid and the use thereof


A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of anisomelic acid or salts thereof. The pharmaceutical composition may comprise anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof.

05/19/16
20160136119 
new patent

Dp2 antagonist and uses thereof


Described herein is the dp2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the dp2 antagonist, or a pharmaceutically acceptable salt thereof.
Brickell Biotech, Inc.


05/19/16
20160136115 
new patent

T type calcium channel inhibitors


The present invention provides novel t type calcium channel inhibitors of formula (i), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via t type calcium channels, wherein r1 is c1-c4 alkyl, hydroxy, or c1-c4 alkoxy; z is nh, nch3, o, s, or ch2; y is nh, o, or ch2 with the proviso that y and z are not the same; r2 is h, halo, nh2, c1-c4 alkyl, hydroxy, or c1-c4 alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m+n=an integer ranging from 2-9; and r3 is h, halo, nh2, c1-c4 alkyl, hydroxy, or c1-c4 alkoxy.. .
University Of Virginia Patent Foundation


05/19/16
20160135987 
new patent

Method and controlling the inner temperature of a patient


The invention relates to a method and apparatus for controlling the inner temperature of a patient, comprising the steps of creating a fluid circuit that comprises a patient and a heat exchanger, the power supply thereto being controlled by a controller; subjecting at least a portion of the fluid in said circuit to the heat exchanger; directing the subjected fluid to and into the patient to control the temperature of the patient; estimating the organ temperature of the patient by a model that has been obtained on a mammal other than the patient; and controlling the power supply to the heat exchanger such that the estimated organ temperature does not exceed a threshold organ temperature, potentially taking into account estimated future organ temperatures. The invention further relates to a method and apparatus for controlling the inner temperature of a patient when subject to whole body hyperthermia, and to a method for obtaining the model..
Vither Hyperthermia B.v.


05/19/16
20160135857 
new patent

Curved tibiotalar fusion nail and use


A tibiotalar fusion system includes that includes a curved fusion nail and interlocking fasteners, along with delivery instrumentation. The curved ankle fusion nail is delivered with the fasteners in such a manner that the curved ankle fusion nail does not pass through the subtalar (talocalcaneal) joint.
Cmarr Enterprises


05/19/16
20160135746 
new patent

Device features and design elements for long-term adhesion


An electronic device for long-term adhesion to a mammal includes a housing with an electronic component. The electronic device may include a first wing and a second wing, each being integrally formed with the housing.
Irythm Technologies, Inc.


05/12/16
20160132631 

Bioinformatic processes for determination of peptide binding


This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes..
Iogenetics, Llc


05/12/16
20160131783 

Bio-acoustic sensing device and marine seismic survey


A method and marine seismic processing system including an interface for receiving recorded data, wherein the recorded data includes seismic data and bio-acoustic data; a seismic data processor for estimating a source signature from the recorded data, wherein the source signature is associated with a seismic source that emits seismic waves in water during a seismic survey; and a bio-acoustic processor that estimates a presence of a mammal generating the bio-acoustic data, based on a processed signal obtained by removing the source signature from the recorded data.. .
Sercel


05/12/16
20160131638 

Immunity to folate receptors


This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing frα immunity in a mammal are provided.
Mayo Foundation For Medical Education And Research


05/12/16
20160130668 

Detection of lethality gene for improved fertility in mammals


Oligonucleic acid molecules comprising a snp site at a position corresponding to position 7480 of the bovine signal transducer and activator of transcription (stat5a) coding sequence (seq id no: 1). Also disclosed are an array or a kit comprising the same, a method for detecting the snps, a method for progeny testing of mammals, a method for increasing human and non-human mammal pregnancy rate in natural and artificial reproduction processes.
Wisconsin Alumni Research Foundation


05/12/16
20160130556 

Enhanced differentiation of mesenchymal stem cells


Isolated populations of mesenchymal stem cells (mscs) are provided, including mammalian mesenchymal stem cells (mscs) characterized by the lack of cd54 (cd54−) or low cell-surface cd54 (cd54low). Methods of in vitro cell differentiation and methods of treatment using said isolated populations are also provided..
Escape Therapeutics, Inc.


05/12/16
20160130357 

Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same


Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (cars) that bind to tumor antigens. Also provided are isolated polypeptides and cars encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered t cells in a subject, expanding a population of genetically engineered t cells in a subject, modulating the amount of cytokine secreted by a t cell, reducing the amount of activation-induced calcium influx into a t cell, providing an anti-tumor immunity to a subject, treating a mammal having a muc1-associated disease or disorder, stimulating a t cell-mediated immune response to a target cell population or tissue in a subject, and imaging a muc1-associated tumor..
The University Of North Carolina At Charlotte


05/12/16
20160130330 

Mammalian receptors as targets for antibody and active vaccination therapy against mold infections


The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragments, sirna and vaccine compositions having or directed against a grp78 polypeptide or an antigenic fragment of the polypeptide..
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center


05/12/16
20160130322 

A growth hormone secretagogue receptor based protein, nucleic acids and methods and uses thereof


Ghrelin is a peptide hormone that binds its receptor, growth hormone secretatgogue receptor 1a (ghs-r1 a, ghrelin receptor), to promote adiposity and obesity in mammals. Ghrelin and its receptor are targets for therapeutic intervention to treat obesity-related disease and cancer.

05/12/16
20160130250 

Sulfonyl amide derivatives for the treatment of abnormal cell growth


Wherein r1 to r6, a, b, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals.

05/12/16
20160129258 

Waveform shapes for treating neurological disorders optimized for energy efficiency


Systems and methods for stimulation of neurological tissue apply a stimulation waveform that is derived by a developed genetic algorithm (ga), which may be coupled to a computational model of extracellular stimulation of a mammalian myelinated axon. The waveform is optimized for energy efficiency..
Duke University


05/12/16
20160129138 

Octapod iron oxide nanoparticles as high performance t2 contrast agents for magnetic resonance imaging


Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° c.
Xiamen University


05/12/16
20160129121 

Factor viia-polysialic acid conjugates having prolonged in vivo half-life


The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor viia (fviia) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a fviia molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of fviia, fviii, or fix.
Baxalta Gmbh


05/12/16
20160129116 

Transdermal drug delivery using an osmolyte and vasoactive agent


A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. For example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient.
Biochemics, Inc.


05/12/16
20160129114 

Liquid composition, process for producing the liquid composition, and ectoparasite controlling agent for use in mammals and avians


A liquid composition comprising (a) 21 to 70 parts by weight of a solvent having no nitrogen atom and having a carbonyl or sulfonyl group in the molecule, (b) 30 to 78.9 parts by weight of at least one component selected from the group consisting of a non-cyclic alcohol, an alkylene glycol, a polyalkylene glycol, a triol, a glycol monoacetate and a glycol monoalkyl ether, (c) 0.001 to 30 parts by weight of a physiologically active ingredient, and (d) 0.001 to 49 parts by weight of water.. .
Nippon Soda Co., Ltd.


05/12/16
20160129092 

Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function


A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function.
Omnigen Research, L.l.c.


05/12/16
20160129084 

Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure


The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (ggf2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects..
Acorda Therapeutics, Inc.


05/12/16
20160129081 

Oral treatment of inflammatory bowel disease


Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from ibd in remission, prolong remission in said subject suffering from ibd, to reduce the occurrence of relapse in said subject suffering from ibd, or any combination thereof, is also described..
Defensin Therapeutics Aps


05/12/16
20160129073 

Method for inhibiting hiv replication in mammal and human cells


The present invention describes a method to inhibit replication of the human immunodeficiency virus (hiv) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-la the replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering rna and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the hiv infection.
Centro De Ingeniería Genetica Y Biotecnología


05/12/16
20160129051 

Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment


Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating tgf β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues.
Tissuetech, Inc.


05/12/16
20160129050 

Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition


Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating tgf β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues.
Tissuetech, Inc.


05/12/16
20160129049 

Purified amniotic membrane compositions and methods of use


Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating tgf β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues.
Tissuetech, Inc.


05/12/16
20160129039 

Process for the preparation of a non-corrosive base solution and methods of using same


The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production including, but not limited to, gout, lesch-nyhan syndrome, hemochromatosis, alzheimer's, amyotropic lateral sclerosis, arthritis, atherosclerosis, cancer, cataracts, chronic obstructive pulmonary disease, diabetes, cellulitis, coronary artery disease, heart failure, hypertension, inflammatory bowel disease, macular degeneration, multiple sclerosis, parkinson's, reynaud's phenomenon, reperfusion injury, pancreatic impairment, skin infections, hepatitis c, methicillin-resistant staphylococcus aureus and infection.

05/12/16
20160129038 

Materials and methods for preventing and treating microbe-mediated epithelial disorders


The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as l-glutamine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as pseudomonas aeruginosa by administering high molecular weight polyethylene glycol as well as methods for monitoring the administration of high molecular weight polyethylene glycol, such as in methods of preventing, ameliorating or treating microbe-induced epithelial disorders, as exemplified by gut-derived sepsis.
The University Of Chicago


05/12/16
20160129021 

Sterilization method


The present invention relates to methods of decreasing sperm production in a male mammal by administering an effective amount of shp2 inhibitor to decrease the spermatogonial stem cell (ssc) population. In particular non-limiting embodiments, this method may be used to achieve sterilization.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


05/12/16
20160128983 

Cytotoxic substance for use in combination with radiotherapy in cancer treatment


The present invention provides a substance comprising a preparation of at least one chemotherapeutic or cytotoxic substance for the use in treatment of a disease of a mammalian patient, especially in the treatment of cancer. The invention suggests a symbiotic or synergistic combination of radiotherapy and chemotherapeutic or cytotoxic drug delivery..
Universität Bern


05/12/16
20160128957 

Transdermal drug delivery using an osmolyte and vasoactive agent


A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. For example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient.
Biochemics, Inc.


05/12/16
20160128952 

Pharmaceutical combination


A combination comprising as components (a) the compound 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) paracetamol or a derivative thereof, a pharmaceutical formulation and a dosage form comprising said combination as well as a method of treating pain, e.g. Chronic or acute pain, characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration..
Gruenenthal Gmbh


05/12/16
20160128933 

Therapeutic methods and compositions


Methods and compositions are described for stimulating therapeutic points of a mammal subject by applying therapeutically effective amount of one or more trp channel agonists.. .

05/12/16
20160128926 

Compositions and methods for treating nails, claws, and hoofs


The present approach relates to compositions and methods for treating fingernails, toenails, hoofs, claws and the like, in mammals. More particularly, the present approach relates to compositions and methods including a prostaglandin analog active ingredient and a carrier.
Topical Solutions, Inc.


05/12/16
20160128865 

System for providing treatment to a mammal and method


Therapy system for treatment of an animate body including core body cooling. The system includes a therapy wrap and a first therapy device for exchanging heat with the body.

05/05/16
20160124000 

Detection of protein to protein interactions


The present invention relates to methods and kits for detecting the interaction between a first membrane protein and a second protein in mammalian cells as well as to identify molecules that can disrupt protein to protein interactions. The invention relies on the functional reconstitution of an active human ubiquitin by two inactive fragments upon the interaction of two proteins attached through a linker to the inactive fragments.
The Governing Council Of The University Of Toronto


05/05/16
20160123979 

Biomarkers for early diagnosis and differentiation of mycobacterial infection


Mycobacterial-specific biomarkers and methods of using such biomarkers for diagnosis of mycobacterial infection in a mammal are disclosed.. .
Wisconsin Alumni Research Foundation


05/05/16
20160122762 

Methods of treating atherosclerosis


Certain embodiments of the invention provide a method of treating endothelial dysfunction, cardiovascular disease and/or atherosclerosis in a mammal, comprising administering an effective amount of a micro-rna-204-5p inhibitor to the mammal.. .
University Of Iowa Research Foundation


05/05/16
20160122718 

Culture medium composition for maturating cardiomyocytes derived from pluripotent mammalian stem cells


The current disclosure relates to a culture medium, different methods to generate adult-like cardiomyocytes from pluripotent embryonic stem cells (esc) and/or (induced) pluripotent stem cells (ipsc) using the medium, in particular from stem cells that differentiated into (foetal) cardiomyocytes, and to kits comprising the medium, or the medium together with differentiated (foetal) cardiomyocytes derived from pluripotent embryonic stem cells (esc) and/or (induced) pluripotent stem cells (ipsc).. .
Pluriomics B.v.


05/05/16
20160122712 

Cell programming


The present invention is concerned with methods for reprogramming of mammalian somatic cells and in particular to reprogramming of mature mammalian somatic cells into multi-potent precursor cells.. .
The University Of Melbourne


05/05/16
20160122707 

Protein modification of living cells using sortase


Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to nongenetically engineered mammalian cells using sortase are provided.
Whitehead Institute For Biomedical Research


05/05/16
20160122336 

Trifluoromethyl alcohols as modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

05/05/16
20160122335 

Amide substituted thiazoles as modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

05/05/16
20160122316 

Serine/threonine kinase inhibitors


Compounds of formula i or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of formula i or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed..
Genentech, Inc.


05/05/16
20160122302 

Mammalian and bacterial nitric oxide synthase inhibitors


Compounds and related methods for inhibition of mammalian and bacterial nitric oxide synthase.. .
Northwestern University


05/05/16
20160121546 

Methods and hygromorphic shape control


A composite film includes a substrate that is not responsive to relative humidity, and also one or more layers of hygromorphic material. The hygromorphic material expands in response to an increase in relative humidity and contracts in response to a decrease in relative humidity.
Massachusetts Institute Of Technology


05/05/16
20160121109 

Transcutaneous neuromodulation system and methods of using same


Neuromodulation systems are described comprising a signal generator and at least one electrode. The at least one electrode can be configured to deliver a stimulation to a mammal, wherein the stimulation includes a biphasic signal and an overlapping high frequency pulse thereby inducing voluntary movement in the individual.
Neuroenabling Technologies, Inc.


05/05/16
20160121030 

Internal clamp for surgical procedures


One aspect of the present invention relates to a method of occluding a vascular site in a mammal comprising the step of introducing into the vasculature of a mammal at or proximal to a surgical site, a composition comprising at least one optionally purified inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily occluding a vascular site of said mammal, wherein said temporarily occluded vasculature site is kept in a substantially cylindrical shape.. .
Genzyme Corporation


05/05/16
20160121016 

Methods and dressings for sealing internal injuries


Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings..
Stb, Ltd.


05/05/16
20160120963 

Bile salt hydrolase bsh1 for regulating weight gain, serum cholesterol levels, and liver triglycerides in a mammal; bacteria strains expressing bsh1 variants


A non-therapeutic method of reducing weight gain, serum cholesterol levels, or liver triglyceride levels, in a non-obese mammal, comprises the step of administering to the gut of a mammal an effective amount of a bacteria expressing a bsh1 enzyme of sequence id no: 1, or a functional variant thereof; a bsh1 enzyme of sequence id no: 1, or a functional variant thereof for use as a medicament; isolated bacterial strains expressing functional variants of bsh1.. .
University College Cork, National University Of Ireland


05/05/16
20160120960 

Adeno-associated virus mediated gene transfer to the central nervous system


A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a raav encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.. .
Regents Of The University Of Minnesota


05/05/16
20160120937 

Pharmaceutical compositions comprising 8-substituted dibenzylbutyrolactone lignans


Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one trail receptor agonist.

05/05/16
20160120934 

Lung injury repair compositions and methods


The present invention provides a pharmaceutical composition comprising protein kinase c zeta (pkc-ζ) inhibitor and therapeutic methods for preventing or treating a pathological condition or symptom or for inducing proliferation of lung progenitor cells in a mammal by administering the pkc-ζ inhibitor.. .
University Of Iowa Research Foundation


05/05/16
20160120931 

Methods and compositions for regulating srca2a expression levels in myocardial infarction


The disclosure provides methods and compositions for increasing serca2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof.
Stealth Biotherapeutics Corp


05/05/16
20160120915 

Methods for manipulating immune responses by altering microbiota


The present invention relates to characterizing changes in mammalian microbiota associated with antibiotic treatments and various immunological conditions and related therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, synbiotics, and antibiotics..
New York University


05/05/16
20160120884 

Pharmaceutical composition for treating disease associated with demyelination of neurons and using the pharmaceutical composition


A method of accelerating remyelination or suppressing demyelination of neurons in a mammal, and a method of treating a disease associated with demyelination of neurons in a mammal.. .
Samsung Electronics Co., Ltd.


05/05/16
20160120875 

Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors


Methods of treatment of disorders of uncontrolled cellular proliferation, including cancer, by administering substituted (e)-n′-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds to mammals in need thereof.. .
University Of Utah Research Foundation


05/05/16
20160120850 

Thiazoles as modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

05/05/16
20160120840 

Method and composition for treating nonerosive reflux disease


Method and composition for treating a nonerosive reflux disease in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative are provided.. .
Sucampo Ag


05/05/16
20160120836 

Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with g-csf or in combination with epo, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and/or anemia..
Hygeia Technology Inc.


05/05/16
20160120801 

Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease


Present invention relates to a low dose pharmaceutical composition, preferably oral composition comprising therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4h,5h-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid (compound a) in the range of 2.5 mg to 60 mg. Present invention also relates to a method of treating inflammatory bowel disease in a mammal by administrating said low dose pharmaceutical composition.
Torrent Pharmaceuticals Limited


05/05/16
20160120691 

Normothermic maintenance method and system


A method of maintaining advantageously stabilized homeostatic parameters through normothermic maintenance in particular in the peri-surgical environment is described. In particular, the method of advantageously applying insulative garments over a small but disproportionately effective percentage of the bsa in order to counter environmentally and surgically induced hypothermia.

05/05/16
20160120643 

Transcatheter cardiac valve prosthetic


A cardiac valve prosthetic effective for use in a living mammalian heart without inducing atrial fibrillation. A plurality of valve leaflets is internally disposed in a radially, compressible stent frame.

05/05/16
20160120433 

Wearable monitor


The present disclosure relates to a wearable monitor device and methods and systems for using such a device. In certain embodiments, the wearable monitor records cardiac data from a mammal and extracts particular features of interest.
Irhythm Technologies, Inc.


05/05/16
20160120183 

Stabilized hypochlorous acid solution and use thereof


Disclosed is an antimicrobial solution comprising, consisting essentially of or consisting of (a) hypochlorous acid, (b) a divalent cation, (c) phosphate anion, and (d) water, as well as a process for its production. Also disclosed is a method of treating or preventing infection associated with abdominal surgery on a mammal, comprising use of the antimicrobial solution..
Oculus Innovative Sciences, Inc


05/05/16
20160120170 

Trehalose and dextran-containing solution for transplanting mammalian cells


The problem of the present invention is to provide a method for preserving mammalian cells over a long period of time using a solution for cell transplantation, capable of effectively suppressing cell death when the mammalian cells have been preserved, and the solution for cell transplantation. The present invention is characterized in that mammalian cells are preserved in a physiological aqueous solution for cell transplantation, comprising 2.0 to 6.0% (w/v) of trehalose, a derivative thereof, or a salt of trehalose or the derivative (a trehalose) and 4.0 to 7.0% (w/v) of dextran, a derivative thereof, or a salt of dextran or the derivative (a dextran).
Otsuka Pharmaceutical Factory, Inc.


04/28/16
20160116467 

Lateral flow assay device


The present invention provides a diagnostic kit for detecting the presence or quantity of one or more test analytes within a test sample taken from a body surface of a mammal, the diagnostic kit comprising: a separate insert for a lateral flow device (200, 411) comprising a membrane (201) fixed to a rigid support (202) and, the separate insert being configured to obtain the test sample; a lateral-flow assay device configured (300, 400) to accept the separate insert (200, 411); a securing member (210) configured to releasably attach (211) the separate insert to a body surface of a mammal (213); wherein the securing member (210) comprise an expandable layer (212) configured to apply pressure to the separate insert (200, 411) thereby pressing the separate insert (200, 411) against the body surface of the mammal (213).. .
Fibrotx OÜ


04/28/16
20160115539 

Use of a slc mammalian skin transporter


The described methods may be useful for identifying topically applied drugs for treatment of skin diseases or as biomarkers for skin diseases. The described methods are intended to assist in characterizing and analyzing the regulation of the expression of solute carrier transporters in mammalian skin..

04/28/16
20160115483 

Silencing of polo-like kinase expression using interfering rna


The present invention provides compositions comprising interfering rna (e.g., sirna, airna, mirna) that target polo-like kinase 1 (plk-1) expression and methods of using such compositions to silence plk-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering rna molecules which silence plk-1 expression and methods of use thereof.
Protiva Biotherapeutics, Inc.


04/28/16
20160115475 

Treatment of insulin resistance through inhibitors of transcription factor tsc22d4


The present invention relates to modulators, in particular inhibitors, of tsc22d4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in mammal. The present invention further relates to screening methods in order to identify these modulators, the use of modulators as identified in the diagnosis of these diseases, as well as kits, comprising materials for performing the methods according to the present invention..
Ruprecht-karls-univeritat Heidelberg


04/28/16
20160115459 

Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins


Chimeric polypeptides useful as immunogens for inducing protective immune responses and neutralizing antibodies against shiga toxin (stx) in mammals. More specifically, chimeric polypeptides having a monomer of the homopentameric b subunit of the shiga 2 toxin fused to the n-terminus of a monomer of brucella lumazine synthase, and to oligomeric protein complexes formed from said chimeric polypeptides.
Inmunova S.a.


04/28/16
20160115458 

Tumor therapy with replication competent sindbis viral vectors


Disclosed herein are methods for treating a mammal harboring a solid tumor which expresses higher levels of high affinity laminin receptors (lamr) than normal cells of the same lineage comprising systematically administering to a mammal in need of such treatment a therapeutically effective amount of a replication competent (rc) sindbis virus vector, wherein said vector encodes a suicide gene.. .
New York University


04/28/16
20160115454 

Isolation, expansion and use of clonogenic endothelial progenitor cells


A hierarchy of endothelial colony forming cells (epcs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential—endothelial colony forming cell (hpp-ecfc) was isolated and characterized.
Indiana University Research And Technology Corporation


04/28/16
20160115220 

Proteolytic release of cell surface antigens for phage biopanning


The invention described herein features methods of isolating monoclonal antibodies or polypeptides that bind to a cell surface expressed antigen. The method of catch and release utilizes engineered protease site for cleavage antigen-antibody or antigen-polypeptide complexes.
The Regents Of The University Of California


04/28/16
20160115218 

Anti-sense oligonucleotides targeted against exon 9 of il-23r-alpha gene and using same to induce exon skipping and to treat inflammatory bowel diseases


The present invention relates to anti-sense oligonucleotides (aons) used to induce exon 9 skipping in il-23rα gene. Exon 9 skipping of the il23rα gene ultimately causes specific induction of a novel soluble truncated il-23rα (Δ9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (glkegsyc) at its c-terminus end as a result of frame-shift.
Medical Diagnostic Laboratories, Llc


04/28/16
20160115178 

Solid forms of a macrocyclic kinase inhibitor


This invention relates to crystalline solvates of (10r)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2h-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to pharmaceutical compositions comprising such crystalline solvates, and to methods of using such solvates and compositions in the treatment of abnormal cell growth in mammals, especially humans..
Pfizer Inc.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4148

4241

1 - 1 - 101